GnRH analog

ApprovedSmall molecule

MMemorial Sloan Kettering Cancer Center

GnRH analog is one of 44 small molecule programs targeting Adenomyosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenomyosisActive, not recruiting

Prostate CancerActive, not recruiting

AdenomyosisApproved

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

GnRH analog

MMemorial Sloan Kettering Cancer Center

Approved

3 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Prostate Cancer

NCT04262154

Q3 2029

Phase 2Active, not recruiting

Prostate Cancer

NCT03809000

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Completed·MMedical University of South Carolina·Phase 1·NCT00099086·20 enrolled

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting·RRTOG Foundation, Inc.·Phase 2·NCT03809000·188 enrolled

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04262154·28 enrolled

Embryo1 trial

DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore

Completed·IIVI Madrid·N/A·NCT03291821·136 enrolled

Adenomyosis1 trial

Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis

Active, not recruiting·CCentre for Endocrinology and Reproductive Medicine, Italy·Phase 4·NCT03421639·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GnRH analog. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GnRH analog compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GnRH analog. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMemorial Sloan Kettering Cancer Center

GnRH analog

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2029

Trials by Indication[1]

Prostate Cancer3 trials

Embryo1 trial

Adenomyosis1 trial

References

Drug Info

Quick Facts

Related News